Clinuvel Pharmaceuticals (CUV) H2 2025 earnings summary

Executive summary

• Achieved ninth consecutive annual profit and eighth consecutive annual dividend, with the fourth fully franked, alongside strong global growth and controlled expenses in FY2025.

• Revenue grew 10% year-over-year to $105.3 million, surpassing the $100 million mark, driven by SCENESSE® demand in Europe and the USA.

• Continued reinvestment in R&D and clinical programs, particularly Phase III for vitiligo, to support future growth.

• Expansion of trained and accredited sites in North America to 104, targeting 120 by year-end.

• Significant reinvestment in personnel and brand visibility to support future growth.

Financial highlights

• Total revenues increased 10% year-over-year to $105.3 million; net profit after tax up 2% to $36.2 million; net profit margin reached 34%.

• Cash reserves rose 22% to $224.1 million; net tangible assets per share increased 19% to $4.77.

• Basic EPS was $0.72, up 1% year-over-year; annual franked dividend maintained at $0.05 per share.

• No capital raised or dilutionary events since 2016; company remains debt-free for 20 years.

• Expenditure increased 20% as forecast, with personnel costs up 31% and commercial distribution costs up 10%.

Outlook and guidance

• Three-year budget to be released in H2 2025, with internal targets of $50–$55 million annual expenditures.

• Cash reserves provide operational coverage for 3–4 years, supporting R&D and potential acquisitions.

• Key upcoming milestones: Health Canada and EMA decisions on SCENESSE®, vitiligo trial updates, and first CUV105 readout in H2 2026.

• Plans to upgrade ADR level and list 8% of U.S. shareholdings on NASDAQ.